Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis

The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholant...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Oncoimmunology Ročník 6; číslo 2; s. e1267892
Hlavní autoři:	Putz, Eva M., Guillerey, Camille, Kos, Kevin, Stannard, Kimberley, Miles, Kim, Delconte, Rebecca B., Takeda, Kazuyoshi, Nicholson, Sandra E., Huntington, Nicholas D., Smyth, Mark J.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Taylor & Francis 01.02.2017 Taylor & Francis Group
Témata:	Cancer cytokine signaling immunotherapy metastasis NK cells Original Research cytokine signaling NK cells metastasis immunotherapy Cancer
ISSN:	2162-402X, 2162-4011, 2162-402X
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in Cish-deficient mice. The combination of Cish deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy.
AbstractList	The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in Cish-deficient mice. The combination of Cish deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy. The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in Cish-deficient mice. The combination of Cish deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy.The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. Cish-deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in Cish-deficient mice. The combination of Cish deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy. The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS in suppressing natural killer (NK) cell control of tumor initiation and metastasis. -deficient mice were highly resistant to methylcholanthrene-induced sarcoma formation and protected from lung metastasis of B16F10 melanoma and RM-1 prostate carcinoma cells. In contrast, the growth of primary subcutaneous tumors, including those expressing the foreign antigen OVA, was unchanged in -deficient mice. The combination of deficiency and relevant targeted and immuno-therapies such as combined BRAF and MEK inhibitors, immune checkpoint blockade antibodies, IL-2 and type I interferon revealed further improved control of metastasis. The data clearly indicate that targeting CIS promotes NK cell antitumor functions and CIS holds great promise as a novel target in NK cell immunotherapy.
Author	Putz, Eva M. Stannard, Kimberley Nicholson, Sandra E. Guillerey, Camille Huntington, Nicholas D. Smyth, Mark J. Miles, Kim Kos, Kevin Delconte, Rebecca B. Takeda, Kazuyoshi
Author_xml	– sequence: 1 givenname: Eva M. surname: Putz fullname: Putz, Eva M. organization: Immunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute – sequence: 2 givenname: Camille surname: Guillerey fullname: Guillerey, Camille organization: School of Medicine, The University of Queensland – sequence: 3 givenname: Kevin surname: Kos fullname: Kos, Kevin organization: Immunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute – sequence: 4 givenname: Kimberley surname: Stannard fullname: Stannard, Kimberley organization: Immunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute – sequence: 5 givenname: Kim surname: Miles fullname: Miles, Kim organization: Immunology of Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute – sequence: 6 givenname: Rebecca B. surname: Delconte fullname: Delconte, Rebecca B. organization: Department of Medical Biology, The University of Melbourne – sequence: 7 givenname: Kazuyoshi orcidid: 0000-0002-5539-310X surname: Takeda fullname: Takeda, Kazuyoshi organization: Department of Immunology, Juntendo University School of Medicine – sequence: 8 givenname: Sandra E. surname: Nicholson fullname: Nicholson, Sandra E. organization: Department of Medical Biology, The University of Melbourne – sequence: 9 givenname: Nicholas D. surname: Huntington fullname: Huntington, Nicholas D. organization: Department of Medical Biology, The University of Melbourne – sequence: 10 givenname: Mark J. surname: Smyth fullname: Smyth, Mark J. email: Mark.Smyth@qimrberghofer.edu.au organization: School of Medicine, The University of Queensland
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28344878$$D View this record in MEDLINE/PubMed
BookMark	eNqFUttu1DAQjVARLaWfAPIjL7v4EieOkBBoxWVFBQ8UiTdrYk-2bhN7sb1F-_cke0EtD2BZ8mhmzjnWzHlanPjgsSieMzpnVNFXnFW8pPzHnFNWzRmvatXwR8XZlJ9NhZN78WlxkdINHU9FZSWaJ8UpV6IsVa3OCn8FcYXZ-RUx2xxunUeS3MpDv0tdo7ldB-czWSy_ETDZ3UHGRL58Jgb7PpEcyDqGjCaTLoaB5M0QInHeZQfZBU_AWzJghjRel54VjzvoE14c3vPi-4f3V4tPs8uvH5eLd5czU1GaZ1gqRVVnW4HjjyUiNNZaxSSq1grLDRhGO1PhWJYolZVGda0ypuPWAkNxXiz3vDbAjV5HN0Dc6gBO7xIhrjTE7EyPupRQtyVXnKm6rDpoUFWl7GphBRfQypHrzZ5rvWkHtAZ9jtA_IH1Y8e5ar8KdlkKKRkwELw8EMfzcYMp6cGkaH3gMm6SZUmxcR9VMrS_ua_0ROS5sbHi9bzAxpBSx08bl3aRHaddrRvXkEH10iJ4cog8OGdHyL_RR4H-4t3uc812IA_wKsbc6w7YPsYvgjUta_JviN_eS1bo
CitedBy_id	crossref_primary_10_1172_JCI162530 crossref_primary_10_1007_s00262_021_02857_z crossref_primary_10_3390_biomedicines9060690 crossref_primary_10_1111_imcb_12390 crossref_primary_10_3390_cancers11071040 crossref_primary_10_1038_s41388_022_02562_w crossref_primary_10_1080_2162402X_2017_1386826 crossref_primary_10_3389_fimmu_2022_802906 crossref_primary_10_1016_j_lfs_2023_121997 crossref_primary_10_1016_j_ccell_2025_05_011 crossref_primary_10_1016_j_immuni_2020_09_010 crossref_primary_10_3389_fimmu_2019_02456 crossref_primary_10_1111_apha_13102 crossref_primary_10_3390_cells10092250 crossref_primary_10_1002_JLB_2MA0620_074R crossref_primary_10_1093_abt_tbaf019 crossref_primary_10_1016_j_coi_2023_102364 crossref_primary_10_1038_s41598_018_23549_2 crossref_primary_10_1016_j_cyto_2017_10_025 crossref_primary_10_1016_j_rvsc_2022_03_012 crossref_primary_10_3389_fmed_2021_727987 crossref_primary_10_1038_s41590_021_00943_z crossref_primary_10_1016_j_compbiomed_2025_109869 crossref_primary_10_3389_fimmu_2018_00527 crossref_primary_10_1016_j_ccell_2017_06_009 crossref_primary_10_1016_j_stem_2020_05_008 crossref_primary_10_3389_fimmu_2019_01999 crossref_primary_10_1182_blood_2020007748 crossref_primary_10_3390_cancers11122002 crossref_primary_10_1080_08923973_2020_1742733 crossref_primary_10_5306_wjco_v14_i10_420 crossref_primary_10_3390_cancers14143356 crossref_primary_10_3390_cancers15082323 crossref_primary_10_3389_fimmu_2019_02590 crossref_primary_10_1007_s13402_020_00523_7 crossref_primary_10_3390_cancers13164129 crossref_primary_10_3390_cancers12040893 crossref_primary_10_1007_s13353_024_00880_1 crossref_primary_10_1080_08977194_2018_1518324 crossref_primary_10_1038_s41590_023_01718_4 crossref_primary_10_1007_s12672_025_02844_1 crossref_primary_10_1016_j_it_2022_08_004 crossref_primary_10_1016_j_imlet_2019_01_011 crossref_primary_10_1002_cti2_1238 crossref_primary_10_1002_JLB_MA0718_296R crossref_primary_10_3390_cells13231976 crossref_primary_10_1016_j_cyto_2018_03_033 crossref_primary_10_3390_cells10051058 crossref_primary_10_1016_j_intimp_2020_106211
Cites_doi	10.1038/ni.3470 10.4161/onci.23036 10.1016/j.coi.2015.10.009 10.1038/ni.2850 10.1038/nrclinonc.2015.209 10.1002/j.1460-2075.1995.tb07281.x 10.1084/jem.20150304 10.1038/ni.3518 10.1126/scitranslmed.3007240 10.1073/pnas.1424241112 10.1172/JCI77181 10.1158/0008-5472.CAN-14-1339 10.1158/1078-0432.CCR-13-0545 10.1056/NEJMoa1504030 10.1074/jbc.274.42.30266 10.1038/ncomms5539 10.1084/jem.188.9.1611 10.1080/2162402X.2014.998119 10.1038/ni.2633 10.1080/2162402X.2015.1027468 10.1182/blood.V89.9.3148 10.1084/jem.20081752 10.1158/0008-5472.CAN-10-1736 10.1158/2159-8290.CD-15-0944 10.1038/nri3799 10.1038/nri3174 10.1084/jem.191.6.985
ContentType	Journal Article
Copyright	2017 Taylor & Francis Group, LLC 2017 2017 Taylor & Francis Group, LLC 2017 Taylor & Francis Group, LLC
Copyright_xml	– notice: 2017 Taylor & Francis Group, LLC 2017 – notice: 2017 Taylor & Francis Group, LLC 2017 Taylor & Francis Group, LLC
DBID	AAYXX CITATION NPM 7X8 5PM DOA
DOI	10.1080/2162402X.2016.1267892
DatabaseName	CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ)
DatabaseTitle	CrossRef PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
DocumentTitleAlternate	E. M. PUTZ ET AL
EISSN	2162-402X
ExternalDocumentID	oai_doaj_org_article_45a7b428218746fa9e8645f73d323ab5 PMC5353935 28344878 10_1080_2162402X_2016_1267892 1267892
Genre	Original Article Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	00X 0YH 53G AAKDD ABUPF ACGFS ADBBV ADCVX AENEX AIJEM ALMA_UNASSIGNED_HOLDINGS AOIJS AQTUD BABNJ BLEHA CCCUG DEAQA DGEBU DGFLZ EBS EJD EMOBN EUPTU GROUPED_DOAJ H13 HYE KRBQP KSSTO KTTOD KWAYT KYCEM M4Z O9- OK1 RPM TDBHL TFL TFW TNTFI TTHFI 4.4 AAYXX CITATION LJTGL OVD TEORI ABDBF ACUHS EBD NPM 7X8 5PM
ID	FETCH-LOGICAL-c600t-e48808fdb3e5635eea9ddd815e8bd3d2cac10fc6ee565e58d5c8fb8ccf2dda1e3
IEDL.DBID	TFW
ISICitedReferencesCount	57
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000397987000018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2162-402X 2162-4011
IngestDate	Mon Nov 10 04:23:28 EST 2025 Tue Nov 04 01:58:04 EST 2025 Sun Aug 24 04:13:27 EDT 2025 Thu Apr 03 06:57:54 EDT 2025 Sat Nov 29 03:25:32 EST 2025 Tue Nov 18 22:13:53 EST 2025 Mon Oct 20 23:44:38 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	cytokine signaling NK cells metastasis immunotherapy Cancer
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c600t-e48808fdb3e5635eea9ddd815e8bd3d2cac10fc6ee565e58d5c8fb8ccf2dda1e3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Supplemental data for this article can be accessed on the publisher's website.
ORCID	0000-0002-5539-310X
OpenAccessLink	https://doaj.org/article/45a7b428218746fa9e8645f73d323ab5
PMID	28344878
PQID	1881448695
PQPubID	23479
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_5353935 proquest_miscellaneous_1881448695 crossref_primary_10_1080_2162402X_2016_1267892 doaj_primary_oai_doaj_org_article_45a7b428218746fa9e8645f73d323ab5 informaworld_taylorfrancis_310_1080_2162402X_2016_1267892 pubmed_primary_28344878 crossref_citationtrail_10_1080_2162402X_2016_1267892
PublicationCentury	2000
PublicationDate	2017-02-01
PublicationDateYYYYMMDD	2017-02-01
PublicationDate_xml	– month: 02 year: 2017 text: 2017-02-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Oncoimmunology
PublicationTitleAlternate	Oncoimmunology
PublicationYear	2017
Publisher	Taylor & Francis Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis – name: Taylor & Francis Group
References	cit0011 cit0012 cit0010 cit0019 cit0017 cit0018 cit0015 cit0016 cit0013 cit0014 cit0022 cit0001 cit0023 cit0020 cit0021 Yoshimura A (cit0007) 1995; 14 cit0009 cit0006 cit0004 Matsumoto A (cit0008) 1997; 89 cit0026 cit0005 cit0027 cit0002 cit0024 cit0003 cit0025
References_xml	– ident: cit0011 doi: 10.1038/ni.3470 – ident: cit0020 doi: 10.4161/onci.23036 – ident: cit0002 doi: 10.1016/j.coi.2015.10.009 – ident: cit0026 doi: 10.1038/ni.2850 – ident: cit0001 doi: 10.1038/nrclinonc.2015.209 – volume: 14 start-page: 2816 year: 1995 ident: cit0007 publication-title: EMBO J doi: 10.1002/j.1460-2075.1995.tb07281.x – ident: cit0013 doi: 10.1084/jem.20150304 – ident: cit0024 doi: 10.1038/ni.3518 – ident: cit0022 doi: 10.1126/scitranslmed.3007240 – ident: cit0025 doi: 10.1073/pnas.1424241112 – ident: cit0015 doi: 10.1172/JCI77181 – ident: cit0021 doi: 10.1158/0008-5472.CAN-14-1339 – ident: cit0018 doi: 10.1158/1078-0432.CCR-13-0545 – ident: cit0003 doi: 10.1056/NEJMoa1504030 – ident: cit0009 doi: 10.1074/jbc.274.42.30266 – ident: cit0010 doi: 10.1038/ncomms5539 – ident: cit0014 doi: 10.1084/jem.188.9.1611 – ident: cit0023 doi: 10.1080/2162402X.2014.998119 – ident: cit0012 doi: 10.1038/ni.2633 – ident: cit0027 doi: 10.1080/2162402X.2015.1027468 – volume: 89 start-page: 3148 year: 1997 ident: cit0008 publication-title: Blood doi: 10.1182/blood.V89.9.3148 – ident: cit0017 doi: 10.1084/jem.20081752 – ident: cit0019 doi: 10.1158/0008-5472.CAN-10-1736 – ident: cit0006 doi: 10.1158/2159-8290.CD-15-0944 – ident: cit0004 doi: 10.1038/nri3799 – ident: cit0005 doi: 10.1038/nri3174 – ident: cit0016 doi: 10.1084/jem.191.6.985
SSID	ssj0000605639
Score	2.3457804
Snippet	The cytokine-induced SH2-containing protein CIS belongs to the suppressor of cytokine signaling (SOCS) protein family. Here, we show the critical role of CIS...
SourceID	doaj pubmedcentral proquest pubmed crossref informaworld
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	e1267892
SubjectTerms	Cancer cytokine signaling immunotherapy metastasis NK cells Original Research
SummonAdditionalLinks	– databaseName: Directory of Open Access Journals (DOAJ) dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3daxwhEJcSWuhL6XevX1jo6yarnrv62IaGlsJRaAr3Jq6OZEmyG269QP77Ou7ecRcK99JXXRedGfWnzvyGkM_BB829wzd1pdMBpXKFVl4UNi2XYGvh5tbnZBP1YqGWS_1rJ9UX-oSN9MCj4E7m0tZNwsgck8dVwWpQ1VyGWnjBhW0ye2lCPTuHqXENThu70JuQHVWecFbhQ8ISvbmqY8bTIq353maUOfvvMZb-C3fed5_c2Y_OnpInE5CkX8YBPCMPoHtOHo2pJe9ekO48u3injYm6u9hfJjBJ0VfDXuWiC3CXN33bRXr64zfF4IZbBJ108ZPiVf5AY08nCgeKESg0rq_7FW3R1SjrktrO02uINqHLoR1ekj9n385PvxdTboXCJYgTC8CJq4JvBCRBSQCrvfeKSVCNF54761gZXAWpWoJUXjoVGuVc4N5bBuIVOer6Dt4QGkrQpQ0uNKCRUEyxEBQrHeONkk7bGZlvhGzcRDyO-S-uDJv4STe6MagbM-lmRo63zW5G5o1DDb6iBrcfI3F2LkjmZCZzMofMaUb0rv5NzPcmYUxyYsSBDnzaGItJkxTVZTvo14NhSSjpHFzp9P_Xo_Fsu8kx04mq1YzUe2a1N479mq69yETgUkiMrH77Pwb-jjzmiFiyQ_p7chRXa_hAHrrb2A6rj3l2_QXhhCe2 priority: 102 providerName: Directory of Open Access Journals
Title	Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis
URI	https://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1267892 https://www.ncbi.nlm.nih.gov/pubmed/28344878 https://www.proquest.com/docview/1881448695 https://pubmed.ncbi.nlm.nih.gov/PMC5353935 https://doaj.org/article/45a7b428218746fa9e8645f73d323ab5
Volume	6
WOSCitedRecordID	wos000397987000018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAWR databaseName: Taylor & Francis Journals Complete customDbUrl: eissn: 2162-402X dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000605639 issn: 2162-402X databaseCode: TFW dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagAokLlPdCuzIS15TYXif2ESpWVEgrJBaxN8vxg0Ztk2qTrdR_j8dxVt0K1ANc49iyx-Px2P7mG4Tee-sltQbe1IUMB5TCZFJYlulgLp0umZlpG5NNlIuFWK3kt4Qm7BKsEs7QfiCKiLYaFreuuhER94GSAt4EVgDMKo4IDfZWghUOnj3o-HL-c3vLkgdvPezBY-jO3yrvbEqRu_8Wc-mf_M_bMMob-9L8yX8Y0T56nJxS_HHQoqfonmueoYdDmsrr56hZRrh42OSwue7bs9A-BtyHPo-fTp05u2zrpsfHJ98xBEpcgQOLF18xPAt0uG9xooPAEM2C-81Fu8Y1wJaiXuDQb3zheh081a7uXqAf88_L4y9ZytOQmeAu9ZkDIyC8rZgLwubOaWmtFYQ7UVlmqdGG5N4ULhRzx4XlRvhKGOOptZo49hLtNW3jXiPscydz7Y2vnARyMkG8FyQ3hFaCG6knaDZOlDKJxBxyaZwrkrhOR1EqEKVKopygo221y4HF464Kn0ALtj8DCXf80K5_qbSm1YzrsgrHNwp5DQuvpRPFjPuSWUaZrvgEyZs6pPp4B-OHhCmK3dGBd6PCqbDgYbp049pNp0gQSjhTFzK0_2pQwG03KWRNEaWYoHJHNXfGsVvS1KeRVJwzDlHab_6hz2_RIwpOT8S0H6C9fr1xh-iBuerrbj1F98uVmMY7j2lcpL8Bgow7NQ
linkProvider	Taylor & Francis
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYq2qpcoE_YPl2p19DYXif2sUWsQNC9dKvuzXL8KBGQoE0WiX9fj5OsdlErDu01iRN7Mp4Z2998g9Anb72k1sCZupBhgZKZRArLEh3MpdM5M2NtY7GJfDoV87lcz4UBWCWsoX1HFBFtNUxu2IweIHGfKcngUGAOyKzsgNBgcGUwww958LUA65tNfq72WdIQrwcvPCTv_K31hluK7P13uEv_FIHeBVKueabJ7v8Y01O008el-EunSM_QA1c9R4-7SpW3L1A1i4jx4OewuW3ri_ABDNAPfRkvnTtzcV2XVYsPT75jyJW4gRgWT08xnAw0uK1xzwiBIaEFt8ureoFLQC5F1cCh4_jKtToEq03ZvEQ_Jkezw-OkL9WQmBAxtYkDOyC8LZgL0ubOaWmtFYQ7UVhmqdGGpN5kLtzmjgvLjfCFMMZTazVx7BXaqurK7SPsUydT7Y0vnAR-MkG8FyQ1hBaCG6lHaDz8KWV6HnMop3GpSE93OohSgShVL8oROlg1u-6IPO5r8BXUYPUw8HDHC_Xil-qntRpznRdhBUehtGHmtXQiG3OfM8so0wUfIbmuRKqN2zC-q5mi2D0d-DhonApzHn6Xrly9bBQJQgnL6kyG9-91GrjqJoXCKSIXI5Rv6ObGODbvVOV55BXnjEOi9ut_6PMH9OR49u1MnZ1MT9-gbQoxUIS4v0Vb7WLp3qFH5qYtm8X7OEt_A1MVPXk
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9wgEEZV-lAuSZ_J9kmlXp0aWGw4tklXjVKtInWr7g1hHo2VxF6tvZHy78tge5WNWuXQXo1BMAzDAN98g9AHb72k1sCbupDhgJKZRArLEh3MpdM5M2NtY7KJfDoV87k87dGETQ-rhDO074gioq2Gxb2wfkDEfaQkgzeBOQCzsgNCg72VwQrfj-RYQaVnk5_ra5Y0uOthEx5id_5We2NXiuT9t6hL_-SA3sZR3tiYJrv_YUiP0U7vleJPnRo9Qfdc9RQ97PJUXj9D1SzixcMuh811W5-H9jEAP_RF_HTmzPmiLqsWHx5_xxApcQUeLJ6eYHgXaHBb454PAkM4C25Xl_USl4BbioqBQ7_xpWt1cFWbsnmOfky-zA6_Jn2ihsQEf6lNHFgB4W3BXBA2d05La60g3InCMkuNNiT1JnOhmDsuLDfCF8IYT63VxLEXaKuqK7ePsE-dTLU3vnAS2MkE8V6Q1BBaCG6kHqHxMFHK9CzmkEzjQpGe7HQQpQJRql6UI3SwrrboaDzuqvAZtGD9M7Bwxw_18pfqF7Uac50X4fxGIbFh5rV0IhtznzPLKNMFHyF5U4dUGy9hfJcxRbE7OvB-UDgVVjxMl65cvWoUCUIJh-pMhvb3OgVcd5NC2hSRixHKN1RzYxybJVV5FlnFOeMQpv3yH_r8Dj06PZqob8fTk1dom4IDFPHtr9FWu1y5N-iBuWrLZvk2rtHfOnc8HQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeting+cytokine+signaling+checkpoint+CIS+activates+NK+cells+to+protect+from+tumor+initiation+and+metastasis&rft.jtitle=Oncoimmunology&rft.au=Putz%2C+Eva+M&rft.au=Guillerey%2C+Camille&rft.au=Kos%2C+Kevin&rft.au=Stannard%2C+Kimberley&rft.date=2017-02-01&rft.issn=2162-4011&rft.volume=6&rft.issue=2&rft.spage=e1267892&rft_id=info:doi/10.1080%2F2162402X.2016.1267892&rft_id=info%3Apmid%2F28344878&rft.externalDocID=28344878
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon